Hong Kong Expands Access to Western, Chinese Covid Medicines
(Bloomberg) -- Hong Kong will distribute oral Covid-19 drugs to doctors and expand the use of traditional Chinese medicine to treat the disease as a deadly wave of omicron infections continues to recede.
Private doctors will be provided with Pfizer Inc.'s Paxlovid and Merck & Co.'s Molnupiravir and encouraged to prescribe them to high-risk patients at no cost, the city's government said in a statement.
The drugs have already been given to more than 22,000 patients in facilities such as hospitals and care homes, it added.
Hong Kong reported 3,709 new coronavirus cases and 111 deaths on Sunday. That was the lowest number of daily cases recorded since Feb. 15, according to data from Johns Hopkins University.
The financial hub has been hit hard by the outbreak which began late January and has killed around 8,000 people so far.
Hong Kong's top official Carrie Lam said at a briefing on Sunday that the city would make it easier for coronavirus patients to obtain traditional Chinese remedies. There are “obstacles in the law” to the wider use of such medicines, an issue which will need to be “solved,” she added.
After the city's retail sales were hit by the wave of infections, the government will distribute consumption vouchers to around 6.3 million people from April 7, finance minister Paul Chan said in an online statement. The vouchers will be worth HK$5,000 ($638).
©2022 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
